ABK Biomedical plans Missouri site for Eye90 Y-90 microspheres
The Ashland, MO, facility will support commercial-scale production of Eye90 microspheres, a Y-90 radioembolization device in clinical development for liver cancer.
ABK Biomedical is partnering with COR Development to establish a commercial manufacturing facility for Eye90 microspheres in Ashland, MO. The site will be located at Cartwright Business Park and constructed by Coil Construction.
Eye90 microspheres are a Y-90 radioembolization device in clinical development for liver cancer treatment. The Missouri facility will serve as ABK’s commercial-scale production site as the company advances the device toward full commercialization.
Site selection was partly driven by proximity to the University of Missouri Research Reactor, or MURR. ABK said MURR is the only domestic producer of the Y-90 radioisotope used in Eye90 microspheres.
The company said the short distance between the Ashland facility and MURR provides a supply-chain advantage for time-sensitive radioisotope production. ABK and MURR recently signed a long-term agreement naming MURR as the primary irradiation partner for Eye90 microspheres.
Eye90 has received U.S. Food and Drug Administration breakthrough device designation, according to ABK. The technology is designed to enable multimodality imaging after implantation, allowing physicians to assess microsphere distribution after the procedure.
ABK’s research page describes Eye90 as using a proprietary imageable glass composition for visualization with fluoroscopy, X-ray, and CT imaging modalities. The company is also developing Eye90 microspheres Precision Dosimetry for imaging and dosimetry analysis in liver tumor treatment.
“Establishing this commercial footprint is another major milestone for ABK,” said Mike Mangano, president and CEO of ABK Biomedical.
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Pathology support broadens MedDream viewer scope
Version 8.9.0 is scheduled for June 2026 through aycan and will add support for pathology workflows and saving reconstructed MPR viewports as new study series.
DOSIsoft unit gives PLANET a theranostics focus
DOSIsoft Theranostics will operate within the DOSIsoft group, with its own partnerships and investment strategy centered on PLANET software.
Vault-ready proton system headed to Tam Anh
Mevion said the S250-FIT installation would be Vietnam’s first proton therapy system, with operation expected as early as late 2027 at Tam Anh’s Phu My Hung facility.
I-MED sale gives Jardines 215-clinic radiology network
Jardine Matheson will acquire 100% of I-MED Radiology Network in a deal valued at A$3.4B, including I-MED’s minority stake in Harrison.ai.
Expected Russell addition puts Hyperfine in small-cap benchmarks
FTSE Russell’s preliminary June reconstitution list includes Hyperfine, with index changes set to take effect after U.S. markets close on June 26.
Curium approach puts Lantheus deal value near $7B
Lantheus is weighing a potential sale after an approach from Curium Pharma, while company filings show recent Pylarify pressure and pending PET regulatory milestones.
Niowave Lansing site to scale Ac-225 supply by 2028
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
30-year GE-UW tie expands into CT and theranostics research
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Recall issues and isotope shortages weigh on Radnostix Q1 revenue
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Ephemeral to build AI data platform for Plus CNS oncology programs
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Fujifilm balloon-free EBUS scope targets pulmonary setup time
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
ACIST Pro brings contrast tracking upgrade to U.S. cath labs
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.